Literature DB >> 11311992

Exogenous surfactant as a drug delivery agent.

J J Haitsma1, U Lachmann, B Lachmann.   

Abstract

Pulmonary surfactant is a complex mixture of lipids and several specific surfactant proteins, which together render it with unique spreading properties and a dynamic surface tension behavior. These characteristics are heralded as ideal for a carrier of choice to instil therapeutic agents into the lung, because this combination enables high local therapeutic levels while minimizing systemic side-effects of the instilled agent. This review outlines the rationale to use exogenous surfactant in lung injury, including opening-up inaccessible regions of the lung to other therapeutic agents. Especially the combination of anti-microbial agents and surfactant offers an alternative for critically ill patients with pneumonia. Some caution is also indicated in combining surfactant with antibiotics without proper evaluation of possible interactions. Some other applications for surfactant as a carrier are discussed. Overall, the benefits of surfactant as a carrier warrants clinical trials and promises additional therapeutic tools for the clinician.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11311992     DOI: 10.1016/s0169-409x(01)00106-5

Source DB:  PubMed          Journal:  Adv Drug Deliv Rev        ISSN: 0169-409X            Impact factor:   15.470


  10 in total

1.  Three-dimensional model of surfactant replacement therapy.

Authors:  Marcel Filoche; Cheng-Feng Tai; James B Grotberg
Journal:  Proc Natl Acad Sci U S A       Date:  2015-07-13       Impact factor: 11.205

2.  Antimicrobial and biophysical properties of surfactant supplemented with an antimicrobial peptide for treatment of bacterial pneumonia.

Authors:  Brandon J H Banaschewski; Edwin J A Veldhuizen; Eleonora Keating; Henk P Haagsman; Yi Y Zuo; Cory M Yamashita; Ruud A W Veldhuizen
Journal:  Antimicrob Agents Chemother       Date:  2015-03-09       Impact factor: 5.191

3.  What's new in critical illness and injury science? State of the art in management of ARDS.

Authors:  Stanislaw P Stawicki; Mamta Swaroop; Sagar C Galwankar; Thomas J Papadimos
Journal:  Int J Crit Illn Inj Sci       Date:  2014-04

4.  The Antibacterial and Anti-inflammatory Activity of Chicken Cathelicidin-2 combined with Exogenous Surfactant for the Treatment of Cystic Fibrosis-Associated Pathogens.

Authors:  Brandon J H Banaschewski; Brandon Baer; Christina Arsenault; Teah Jazey; Edwin J A Veldhuizen; Johan Delport; Tracey Gooyers; James F Lewis; Henk P Haagsman; Ruud A W Veldhuizen; Cory Yamashita
Journal:  Sci Rep       Date:  2017-11-14       Impact factor: 4.379

Review 5.  The future of antisense oligonucleotides in the treatment of respiratory diseases.

Authors:  Marina Ulanova; Alan D Schreiber; A Dean Befus
Journal:  BioDrugs       Date:  2006       Impact factor: 5.807

6.  Optimizing Exogenous Surfactant as a Pulmonary Delivery Vehicle for Chicken Cathelicidin-2.

Authors:  Brandon Baer; Edwin J A Veldhuizen; Natalia Molchanova; Shehrazade Jekhmane; Markus Weingarth; Håvard Jenssen; Jennifer S Lin; Annelise E Barron; Cory Yamashita; Ruud Veldhuizen
Journal:  Sci Rep       Date:  2020-06-10       Impact factor: 4.379

7.  Efficient delipidation of a recombinant lung surfactant lipopeptide analogue by liquid-gel chromatography.

Authors:  Oihana Basabe-Burgos; Jakub Zebialowicz Ahlström; Pavol Mikolka; Michael Landreh; Jan Johansson; Tore Curstedt; Anna Rising
Journal:  PLoS One       Date:  2019-12-04       Impact factor: 3.240

8.  Comparison of Polymyxin E and Polymyxin B as an Additive to Pulmonary Surfactant in Escherichia coli Pneumonia of Ventilated Neonatal Rabbits.

Authors:  Guido Stichtenoth; Marie Haegerstrand-Björkman; Gabi Walter; Bim Linderholm; Egbert Herting; Tore Curstedt
Journal:  Biomed Hub       Date:  2017-06-24

9.  Exogenous pulmonary surfactant as a vehicle for antimicrobials: assessment of surfactant-antibacterial interactions in vitro.

Authors:  Alexei Birkun
Journal:  Scientifica (Cairo)       Date:  2014-04-29

10.  Exogenous Surfactant as a Pulmonary Delivery Vehicle for Budesonide In Vivo.

Authors:  Brandon Baer; Lynda McCaig; Cory Yamashita; Ruud Veldhuizen
Journal:  Lung       Date:  2020-10-26       Impact factor: 2.584

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.